From: Impact of nutritional status in the era of FOLFOX/FIRI-based chemotherapy
n = 108 | |||
---|---|---|---|
Age | Median (range) | 65 (34–83) | |
Gender (male/female) | 58/50 | ||
Performance status | (0, 1, 2, 3) | (91, 16, 1, 0) | |
Body mass indexa | 23.3 (13.7–36.9) | ||
Primary tumor site | |||
Colon/rectum | 75/33 | ||
Right-sided/left-sided | 51/57 | ||
Residual of primary tumor | 17 (15.7%) | ||
History of liver resection for metastasis | 27 (25.0%) | ||
Number of liver metastasisa | 5 (0–28) | ||
Target lesion of chemotherapy | |||
Primary tumor | 19 (17.6%) | ||
Lymph node | 28 (25.9%) | ||
Peritoneum | 18 (16.7%) | ||
Lung | 29 (26.9%) | ||
Liver | 43 (39.8%) | ||
KRAS status | Wild | 67 (62.0%) | |
First line chemotherapy | FOLFOX/FOLFIRI | 30/78 | |
Add-on targeting agent | VEGFR | 41 (38.0%) | |
EGFR | 38 (35.1%) | ||
None | 29 (26.9%) | ||
Preoperative statusa | |||
White blood cell | (mm3)(mm3) | 6000 (3400–9950) | |
Neutrophil | (mm3)(mm3) | 3887 (1659–3750) | |
Lymphocyte | (mm3)(mm3) | 1352 (512–2195) | |
Albumin | (g/dl) | 3.8 (2.4–4.7) | |
Total bilirubin | (mg/dl) | 0.46 (0.19–3.82) | |
Aspartate aminotransferase | (IU/L) | 23 (12–203) | |
Lactate dehydrogenase | (IU/L) | 196 (21–1949) | |
Blood urea nitrogen | (mg/dL) | 13.7 (4.7–27.7) | |
Creatinine | 0.68 (0.42–1.59) | ||
C-reactive protein | (mg/dL) | 0.45 (0.1–8.94) | |
Carcinoembryonic antigen | (mg/L) | 18.0 (4.7–65.3) | |
CA19-9 | (mg/L) | 35.7 (6.5–129.4) |